☰

High-dose interleukin-2 effective in mRCC pre-treated with VEGF-targeted therapies

High-dose interleukin-2 can be effective in selected metastatic renal cell cancer patients pre-treated with VEGF-targeted agents, reveals research presented at the ESMO Symposium on Immuno-Oncology in Geneva, Switzerland

Fuente : http://www.alphagalileo.org/ViewItem.aspx?ItemId=1...

Lunes, 24 de Noviembre 2014

Jueves, 1 de Enero 1970

1 1

Reacciona. Deja tu comentario

Otros artículos de esta sección

High-dose interleukin-2 effective in mRCC pre-treated with VEGF-targeted therapies

{{date}} {{title}}